We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BASF SE (BASFY): The Perfect Mix of Value and Rising Earnings Estimates?
Read MoreHide Full Article
Value investing is always a very popular strategy, and for good reason. After all, who doesn’t want to find stocks that have low PEs, solid outlooks, and decent dividends?
Fortunately for investors looking for this combination, we have identified a strong candidate which may be an impressive value; BASF SE (BASFY - Free Report) .
BASF SE in Focus
BASFY may be an interesting play thanks to its forward PE of 12.1, its P/S ratio of 1, and its decent dividend yield of 3.6%. These factors suggest that BASF SE is a pretty good value pick, as investors have to pay a relatively low level for each dollar of earnings, and that BASFY has decent revenue metrics to back up its earnings.
But before you think that BASF SE is just a pure value play, it is important to note that it has been seeing solid activity on the earnings estimate front as well. For current year earnings, the consensus has gone up by 21.6% in the past 30 days, thanks to two upward revisions in the past one month compared to none lower.
So really, BASF SE is looking great from a number of angles thanks to its PE below 20, a P/S ratio below one, and a strong Zacks Rank, meaning that this company could be a great choice for value investors at this time.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
BASF SE (BASFY): The Perfect Mix of Value and Rising Earnings Estimates?
Value investing is always a very popular strategy, and for good reason. After all, who doesn’t want to find stocks that have low PEs, solid outlooks, and decent dividends?
Fortunately for investors looking for this combination, we have identified a strong candidate which may be an impressive value; BASF SE (BASFY - Free Report) .
BASF SE in Focus
BASFY may be an interesting play thanks to its forward PE of 12.1, its P/S ratio of 1, and its decent dividend yield of 3.6%. These factors suggest that BASF SE is a pretty good value pick, as investors have to pay a relatively low level for each dollar of earnings, and that BASFY has decent revenue metrics to back up its earnings.
BASF SE PE Ratio (TTM)
BASF SE pe-ratio-ttm | BASF SE Quote
But before you think that BASF SE is just a pure value play, it is important to note that it has been seeing solid activity on the earnings estimate front as well. For current year earnings, the consensus has gone up by 21.6% in the past 30 days, thanks to two upward revisions in the past one month compared to none lower.
This estimate strength is actually enough to push BASFY to a Zacks Rank #1 (Strong Buy), suggesting it is poised to outperform. You can see the complete list of today’s Zacks #1 Rank stocks here.
So really, BASF SE is looking great from a number of angles thanks to its PE below 20, a P/S ratio below one, and a strong Zacks Rank, meaning that this company could be a great choice for value investors at this time.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>